Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia

This publication has 17 references indexed in Scilit:

• The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
  New England Journal of Medicine, 2003
• Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia
  Urology, 2003
• Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients
  European Urology Supplements, 2003
• Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia
  Urology, 1999
• Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years
  Urology, 1999
• A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
  European Urology, 1999
• SELECTIVITY OF FINASTERIDE AS AN IN VIVO INHIBITOR OF 5 alpha-REDUCTASE ISOZYME ENZYMATIC ACTIVITY IN THE HUMAN PROSTATE
  Journal of Urology, 1999
• The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
  New England Journal of Medicine, 1998
• Natural History of Prostatism: Longitudinal Changes in Voiding Symptoms in Community Dwelling Men
  Journal of Urology, 1996
• Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?
  Published by Wolters Kluwer Health ,1995